| scholarly article | Q13442814 |
| P2093 | author name string | Amanda M Farr | |
| Stephen S Johnston | |||
| Donna McMorrow | |||
| Paul Juneau | |||
| Sarika Ogale | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 | ||
| Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study | Q33362177 | ||
| Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? | Q33566367 | ||
| Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study | Q34022346 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Treatment continuation in patients receiving biological agents or conventional DMARD therapy | Q35556040 | ||
| Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden | Q35630063 | ||
| Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings | Q38034134 | ||
| Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. | Q51168531 | ||
| Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. | Q51463411 | ||
| Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. | Q51689568 | ||
| A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity | Q55879648 | ||
| A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry | Q83373545 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 59-71 | |
| P577 | publication date | 2014-12-23 | |
| P1433 | published in | Rheumatology and therapy | Q27727370 |
| P1476 | title | Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic | |
| P478 | volume | 2 |
| Q47367453 | A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. |
| Q90324208 | Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis |
| Q36216285 | Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. |
| Q52642633 | Long-term persistence with rituximab in patients with rheumatoid arthritis. |
| Q39068415 | Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis |
| Q37167818 | Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan |
Search more.